Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R24.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R23.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R25.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R11.htm
EX-3.1 - Q Therapeutics, Inc.ex3-1.htm
EX-3.2 - Q Therapeutics, Inc.ex3-2.htm
EX-32.1 - Q Therapeutics, Inc.ex32-1.htm
EX-32.2 - Q Therapeutics, Inc.ex32-2.htm
EX-14.1 - Q Therapeutics, Inc.ex14-1.htm
EX-31.2 - Q Therapeutics, Inc.ex31-2.htm
EX-31.1 - Q Therapeutics, Inc.ex31-1.htm
10-Q - Q Therapeutics, Inc.form10q.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R15.htm
v2.4.0.6
Condensed Consolidated Balance Sheets (Unaudited) (USD $)
Sep. 30, 2012
Dec. 31, 2011
Current assets:    
Cash $ 1,296,149 $ 2,741,519
Receivable, net of allowance of $0 and $2,282, as of September 30, 2012 and December 31, 2011, respectively 29,238 53,796
Prepaid expenses and other 5,465   
Total current assets 1,330,852 2,795,315
Property and equipment, net 20,199 31,923
Other assets 7,513 7,513
Total assets 1,358,564 2,834,751
Current liabilities:    
Accounts payable 15,986 77,181
Accrued liabilities 12,297 24,212
Accrued compensation 188,320 177,401
Note payable    15,000
Total current liabilities 216,603 293,794
Notes payable 110,360   
Total liabilities 326,963 293,794
Commitments and contingencies     
Stockholders' equity:    
Common stock; $0.0001 par value: 100,000,000 shares authorized; 24,665,083 and 24,582,632 shares issued and outstanding as of September 30, 2012 and December 31, 2011, respectively 2,467 2,458
Additional paid-in capital 20,270,640 19,972,937
Deficit accumulated during the development stage (19,241,506) (17,434,438)
Total stockholders' equity 1,031,601 2,540,957
Total liabilities and stockholders' equity $ 1,358,564 $ 2,834,751